172 related articles for article (PubMed ID: 16710819)
21. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
Harper L
Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
23. Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment.
Zaenker M; Arbach O; Helmchen U; Glorius P; Ludewig S; Braasch E
Int J Tissue React; 2004; 26(3-4):85-92. PubMed ID: 15648440
[TBL] [Abstract][Full Text] [Related]
24. Targeting B lymphocytes as therapy for ANCA-associated vasculitis.
Golbin JM; Specks U
Rheum Dis Clin North Am; 2007 Nov; 33(4):741-54, v. PubMed ID: 18037114
[TBL] [Abstract][Full Text] [Related]
25. [Rapidly progressive glomerulonephritis in ANCA-associated vasculitis: a course, treatment efficacy, prognosis].
Tomilina NA; Biriukova LS; Egorova ET; Sukhanov AV; Stoliarevich ES; Kupavtseva OA; Fedorova ND; Frolov AV; Trushkin RN; Kurenkova LG
Ter Arkh; 2008; 80(6):15-24. PubMed ID: 18655470
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
Walsh M; Jayne D
Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693
[TBL] [Abstract][Full Text] [Related]
27. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases.
Chen YX; Yu HJ; Ni LY; Zhang W; Xu YW; Ren H; Chen XN; Wang XL; Li X; Pan XX; Wang WM; Chen N
J Rheumatol; 2007 Dec; 34(12):2451-6. PubMed ID: 17985400
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis und therapy of ANCA-associated vasculitis].
Aries PM; Hellmich B; Gross WL
Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569
[TBL] [Abstract][Full Text] [Related]
29. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis.
Marinaki S; Kälsch AI; Grimminger P; Breedijk A; Birck R; Schmitt WH; Weiss C; van der Woude FJ; Yard BA
Nephrol Dial Transplant; 2006 Jul; 21(7):1825-32. PubMed ID: 16567340
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Gao Y; Chen M; Ye H; Yu F; Guo XH; Zhao MH
Rheumatology (Oxford); 2008 Oct; 47(10):1515-20. PubMed ID: 18676500
[TBL] [Abstract][Full Text] [Related]
31. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
Flossmann O; de Groot K
Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
[No Abstract] [Full Text] [Related]
32. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
33. Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis.
Gao Y; Chen M; Ye H; Guo XH; Zhao MH; Wang HY
Clin Endocrinol (Oxf); 2007 Apr; 66(4):543-7. PubMed ID: 17371473
[TBL] [Abstract][Full Text] [Related]
34. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
35. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
37. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil.
Gao Y; Chen M; Ye H; Guo XH; Zhao MH; Wang HY
Int Immunopharmacol; 2007 Jan; 7(1):55-60. PubMed ID: 17161817
[TBL] [Abstract][Full Text] [Related]
38. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab.
Clatworthy MR; Jayne DR
Am J Kidney Dis; 2006 Apr; 47(4):680-2. PubMed ID: 16564946
[TBL] [Abstract][Full Text] [Related]
39. How to induce remission in primary systemic vasculitis.
Jayne D
Best Pract Res Clin Rheumatol; 2005 Apr; 19(2):293-305. PubMed ID: 15857797
[TBL] [Abstract][Full Text] [Related]
40. Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis.
José RJ; Chrysochou C; Shurrab AE; New D; Wood GN
Scand J Urol Nephrol; 2010 Dec; 44(6):459-62. PubMed ID: 20645677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
